News|Articles|October 26, 2023
Inside Look at Resilience’s Latest Viral Vector Manufacturing Site
Author(s)Resilience
Designed for advanced therapy manufacturing, the Marlborough, MA facility is the first new construction at Resilience. The site will produce, rest, and release viral vector drug substance (DS) and drug product (DP), for clinical and commercial use.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
EMA Calls New EU Pharma Legislation Most Significant in Two Decades
2
European Parliament Revamps Pharmaceutical Policy Framework
3
Tjoapack’s Advanced Packaging Expansion Aims to Meet Rising Demand
4
FDA’s CNPV Pilot Gives First Approval to Antibiotic for Pneumonia and Sinusitis
5
